Anlotinib plus Chemotherapy for the Treatment of Refractory Primary Cardiac Intimal Sarcoma: A Case Report

安罗替尼联合化疗治疗难治性原发性心脏内膜肉瘤:病例报告

阅读:1

Abstract

INTRODUCTION: Primary cardiac intimal sarcoma (CIS) is a rare and highly malignant soft tissue tumor associated with an extremely poor prognosis. To date, there are no established treatment guidelines for CIS in clinical practice. CASE PRESENTATION: A 44-year-old man was diagnosed with left atrial intimal sarcoma. Forty-two days after radical surgical resection, he developed local recurrence accompanied by brain and gluteus medius metastases. The patient first received emergency radiotherapy for intracranial metastases, followed by six cycles of systemic chemotherapy with ifosfamide and epirubicin, combined with targeted therapy using anlotinib. Ultimately, he achieved an overall survival (OS) of 17 months. CONCLUSION: To our knowledge, this is the first report describing the therapeutic efficacy of anlotinib in CIS. This case highlights the potential role of anlotinib as a promising therapeutic option for this rare and aggressive malignancy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。